Effect of Neomycin on the Pharmacokinetics of Regorafenib

NCT02001909 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

27

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: Regorafenib (Stivarga, BAY73-4506)
DRUG: Neomycin

Sponsor

Bayer